Andalusian School of Public Health/Escuela Andaluza de Salud Pública (EASP), Granada, Spain.
Instituto de Investigación Biosanitaria ibs, Granada, Spain.
Eur J Health Econ. 2022 Aug;23(6):979-991. doi: 10.1007/s10198-021-01414-w. Epub 2021 Nov 26.
From both the methodological point of view and standardization of methodology, little attention has been paid to the estimation of direct costs in evaluation of healthcare technologies. The objective is to revise the recommendations on direct costs provided in European economic evaluation guidelines and to identify the commonalities and divergences among them. To achieve this, a comprehensive search through several online databases was performed resulting in 41 documents from 26 European countries, be they economic evaluation guidelines or costing guidelines. The results show a large disparity in methodologies used in estimation of direct costs to be included in economic evaluations of health technologies recommended by European countries. A lack of standardization of cost estimation methodologies influences arbitrariness in selecting costs of resources included in economic evaluations of medicinal products or any other technologies and, therefore, in decision making process necessary to introduce new technology. In addition, this heterogeneity poses a major challenge for identifying factors that could affect the variability of unit costs across countries.
从方法论的角度和方法标准化的角度来看,在医疗技术评估中,直接成本的估计几乎没有得到关注。目的是修订欧洲经济评估指南中关于直接成本的建议,并确定它们之间的共同点和差异。为此,通过几个在线数据库进行了全面搜索,结果来自 26 个欧洲国家的 41 份文件,其中包括经济评估指南或成本指南。结果表明,欧洲国家推荐的卫生技术经济评估中包含的直接成本估计方法存在很大差异。成本估算方法缺乏标准化会影响到在药物或任何其他技术的经济评估中选择包括的资源成本的任意性,因此也会影响到引入新技术所需的决策过程。此外,这种异质性给确定可能影响国家间单位成本可变性的因素带来了重大挑战。